Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT02466490
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 272 participants
- Sponsor
- Stendhal Americas, S.A.
- Registry
-
NCT02466490
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Mexico
- Registry status
- Completed
Technical summary
Registry record NCT02466490. Randomized; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension
- Acronym
- FIRME-1
- Condition
- Hypertension, Essential
- Intervention (Drug)
- Fimasartan
- Intervention (Drug)
- Fimasartan; Hydrochlorothiazide
- Lead sponsor
- Stendhal Americas, S.A.
Record details
- Record id
cardio:ct-nct02466490- Content hash
f0a503d3c86f55663731cf21807ff34526746e50e15a5da8ce44e01ba4b10425